ஆஞ்சியோலஜி: திறந்த அணுகல்
திறந்த அணுகல்

சுருக்கம்

Underuse and Misuse of Newer Antidiabetic Medication with Established Positive Cardiovascular Outcome

Syed Raza

Diabetes is a growing problem globally despite all advances in its management strategy. In the last decade particularly there has been a plethora of newer anti diabetic medications that have been introduced in the market.

Recent trials and studies have shown promising results in terms of cardiovascular event reduction using some newer classes of anti-diabetic medications such as GLP1 agonist and SGLT2 Inhibitors.  There are now well-established guidelines on use of these medications in certain group of patients.  These guidelines are based on several randomized controlled cardiovascular outcome trials. The pathophysiology   of how they work, and their potential benefit are now well understood.

Despite clear recent guidelines, a significant proportion of patients with established or risk of CVD are not on appropriate anti-diabetic medications. There  is  still  lack of  knowledge, awareness  as  well  as  inertia  amongst  healthcare  professionals  in initiating  these  valuable medications  which are  not  only  safe  but  also  effective  and  beneficial.

It is therefore needed that practicing physicians are educated and made aware of the use of these medications. At the same time, they also need to be aware of any side effects and contraindications and therefore use them judiciously.  A wiser decision and choice of these agents should be made in partnership with the patient after they are adequately educated of the proposed new medication.